Viridian Therapeutics, Inc. (NASDAQ:VRDN) CEO Stephen F. Mahoney Acquires 21,400 Shares of Stock

Viridian Therapeutics, Inc. (NASDAQ:VRDN) CEO Stephen F. Mahoney acquired 21,400 shares of the business’s stock in a transaction on Friday, September 27th. The stock was acquired at an average price of $23.33 per share, for a total transaction of $499,262.00. Following the acquisition, the chief executive officer now owns 21,400 shares of the company’s stock, valued at approximately $499,262. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Viridian Therapeutics Stock Down 2.5 %

Shares of Viridian Therapeutics stock opened at $22.75 on Tuesday. The company has a market cap of $1.45 billion, a price-to-earnings ratio of -5.06 and a beta of 1.03. The company’s 50 day moving average is $17.15 and its 200 day moving average is $15.24. Viridian Therapeutics, Inc. has a twelve month low of $10.93 and a twelve month high of $24.18. The company has a quick ratio of 15.82, a current ratio of 15.82 and a debt-to-equity ratio of 0.05.

Viridian Therapeutics (NASDAQ:VRDN) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($1.02) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.15). The company had revenue of $0.07 million for the quarter, compared to the consensus estimate of $0.09 million. Viridian Therapeutics had a negative net margin of 79,185.77% and a negative return on equity of 83.18%. Research analysts anticipate that Viridian Therapeutics, Inc. will post -3.94 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. Maverick Capital Ltd. raised its position in Viridian Therapeutics by 22.9% in the second quarter. Maverick Capital Ltd. now owns 3,307,945 shares of the company’s stock worth $43,036,000 after acquiring an additional 615,531 shares during the period. Vanguard Group Inc. raised its position in Viridian Therapeutics by 7.8% in the first quarter. Vanguard Group Inc. now owns 3,234,279 shares of the company’s stock worth $56,632,000 after acquiring an additional 233,331 shares during the period. Novo Holdings A S raised its position in Viridian Therapeutics by 81.8% in the second quarter. Novo Holdings A S now owns 2,000,000 shares of the company’s stock worth $26,020,000 after acquiring an additional 900,000 shares during the period. Perceptive Advisors LLC raised its position in Viridian Therapeutics by 71.1% in the fourth quarter. Perceptive Advisors LLC now owns 1,730,212 shares of the company’s stock worth $37,684,000 after acquiring an additional 719,007 shares during the period. Finally, Vestal Point Capital LP bought a new position in Viridian Therapeutics in the fourth quarter worth approximately $21,780,000.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the stock. The Goldman Sachs Group upped their price objective on shares of Viridian Therapeutics from $25.00 to $31.00 and gave the stock a “buy” rating in a report on Thursday, September 12th. HC Wainwright reiterated a “buy” rating and set a $27.00 price target on shares of Viridian Therapeutics in a report on Tuesday, September 10th. Wolfe Research started coverage on shares of Viridian Therapeutics in a report on Tuesday, June 11th. They set an “outperform” rating and a $29.00 price target on the stock. Needham & Company LLC increased their price target on shares of Viridian Therapeutics from $30.00 to $38.00 and gave the company a “buy” rating in a report on Wednesday, September 11th. Finally, Wedbush reiterated an “outperform” rating and set a $42.00 price target on shares of Viridian Therapeutics in a report on Monday, July 29th. Two research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat, Viridian Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $35.80.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.